How does the DOJ reclassify medical marijuana?

DOJ eases federal restrictions on medical marijuana

The Justice Department moved to change how state-licensed medical marijuana is classified under federal law, an action that can affect how companies and researchers are able to study cannabis-based therapies.

What changed in federal scheduling

Acting Attorney General Todd Blanche said the Justice Department is reclassifying medical marijuana from Schedule I to Schedule III. Under the new classification, medical marijuana would no longer be treated as a Schedule I substance—federal law often used to characterize drugs like heroin or LSD—and would instead fall into Schedule III, a category that includes certain controlled medicines.

Why it matters

Schedule I status has historically made medical research and certain development efforts harder because of strict regulatory barriers and compliance risks. Moving marijuana to Schedule III is intended to make it easier to conduct research and potentially expand treatment options.

At the same time, the federal change is focused on medical marijuana and its classification, not a broad legalization policy. The reporting describes the move as a regulatory shift that could open the door for more research rather than an immediate overhaul of how marijuana is used commercially.

What to watch next

The practical impact will depend on how federal agencies implement the schedule change and what specific research and clinical development programs are able to proceed more smoothly as a result.

Overall, the DOJ’s scheduling decision is a significant policy signal that the federal government is adjusting its stance toward medical cannabis, with the stated aim of enabling more research and treatment options.